Oppenheimer analyst Suraj Kalia initiated coverage of Pulse Biosciences (PLSE) with an Outperform rating and $22 price target The company has developed nanosecond pulsed field ablation technology and preliminary evidence suggests a better safety and efficacy profile versus traditional treatments in key applications like thyroid ablation, the analyst tells investors in a research note. The firm says Pulse has multiple shots on goal and an experienced CEO.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE: